Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.61 |
| ▸ | TRIM24 | O15164 | 1/20 | 0.53 |
| ▸ | TRIM33 | Q9UPN9 | 1/20 | 0.53 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.51 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.51 |
| ▸ | HRH3 | Q9Y5N1 | 2/20 | 0.42 |
| ▸ | HTR7 | P34969 | 4/20 | 0.41 |
| ▸ | DRD2 | P14416 | 2/20 | 0.41 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21561087 | 0.81 | MAPT (0.58) | HTR7DRD2SIGMAR1 | |
| SCHEMBL377522 | 0.80 | ALDH1A1 (0.63) | ALDH1A1TRIM24TRIM33KDM4ESMN1; SMN2 | |
| SCHEMBL4438019 | 0.80 | MAPT (0.62) | ALDH1A1KDM4ESMN1; SMN2HTR7DRD2 | |
| SCHEMBL6151797 | 0.80 | MAPT (0.62) | ALDH1A1KDM4ESMN1; SMN2HTR7DRD2 | |
| SCHEMBL15599350 | 0.80 | HTR7 (0.51) | HTR7DRD2SIGMAR1 | |
| SCHEMBL8779336 | 0.80 | ALDH1A1 (0.62) | ALDH1A1TRIM24TRIM33KDM4ESMN1; SMN2 | |
| SCHEMBL5356967 | 0.79 | ALDH1A1 (0.66) | ALDH1A1TRIM24TRIM33KDM4ESMN1; SMN2 | |
| SCHEMBL14393753 | 0.79 | ALDH1A1 (0.61) | ALDH1A1TRIM24TRIM33KDM4ESMN1; SMN2 | |
| SCHEMBL19057548 | 0.79 | ALDH1A1 (0.61) | ALDH1A1TRIM24TRIM33KDM4ESMN1; SMN2 | |
| SCHEMBL1983610 | 0.78 | ALDH1A1 (0.60) | ALDH1A1TRIM24TRIM33KDM4ESMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120128630-A1 | 1-(6 MEMBERS AZO-HETEROCYCLIC)-PYRROLIN-2-ONE COMPOUNDS AS INHIBITORS OF HEPATITIS C NS5B POLYMERASE, THE PHARAMACEUTICAL COMPOSITION THEREOF AND THEIR THERAPEUTIC USE | VIVALIS (FR) | 2012-05-24 | — | — | US | disclosed |
| EP-2451800-A1 | 1-(6 MEMBERS AZO-HETEROCYCLIC)-PYRROLIN-2-ONE COMPOUNDS AS INHIBITORS OF HEPATITIS C NS5B POLYMERASE, THE PHARMACEUTICAL COMPOSITION THEREOF AND THEIR THERAPEUTIC USE | Vivalis (FR) | 2012-05-16 | — | — | EP | disclosed |
| WO-2011004017-A1 | 1-(6 MEMBERS AZO-HETEROCYCLIC)-PYRROLIN-2-ONE COMPOUNDS AS INHIBITORS OF HEPATITIS C NS5B POLYMERASE, THE PHARMACEUTICAL COMPOSITION THEREOF AND THEIR THERAPEUTIC USE | VIVALIS (FR) | 2011-01-13 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120128630-A1 | 1-(6 MEMBERS AZO-HETEROCYCLIC)-PYRROLIN-2-ONE COMPOUNDS AS INHIBITORS OF HEPATITIS C NS5B POLYMERASE, THE PHARAMACEUTICAL COMPOSITION THEREOF AND THEIR THERAPEUTIC USE | NAT1, POLM, PYGL | ALDH1A1 1657/4885TRIM24 1930/4885TRIM33 3552/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.